Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Annals of Neurology
|
July 14, 2000
Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy
R Lodi, A H Schapira, D Manners, et al.
Neurology
|
August 23, 2006
Increased rate of whole-brain atrophy over 6 months in early Huntington disease
S M D Henley, C Frost, D G MacManus, et al.
Neurology
|
December 28, 2006
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia
S J Cano, J C Hobart, M Edwards, et al.
Neurology
|
July 23, 2003
A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia
P A Wilkinson, A H Crosby, C Turner, et al.
American Journal of Human Genetics
|
June 5, 2001
The Silver syndrome variant of hereditary spastic paraplegia maps to chromosome 11q12-q14, with evidence for genetic heterogeneity within this subtype
H Patel, P E Hart, T T Warner, et al.
Human Molecular Genetics
|
November 7, 2000
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity
S J Tabrizi, M Orth, J M Wilkinson, et al.
Neurology
|
May 11, 2005
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study
S J Tabrizi, A M Blamire, D N Manners, et al.
Neurology
|
July 9, 2003
Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study
S J Tabrizi, A M Blamire, D N Manners, et al.
Neuropathology and Applied Neurobiology
|
July 29, 2020
Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia
D Hansen, H Ling, T Lashley, et al.
Neurology
|
November 10, 2004
Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58)
S J Cano, T T Warner, J M Linacre, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Annals of Neurology
|
July 14, 2000
Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy
R Lodi, A H Schapira, D Manners, et al.
Neurology
|
August 23, 2006
Increased rate of whole-brain atrophy over 6 months in early Huntington disease
S M D Henley, C Frost, D G MacManus, et al.
Neurology
|
December 28, 2006
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia
S J Cano, J C Hobart, M Edwards, et al.
Neurology
|
July 23, 2003
A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia
P A Wilkinson, A H Crosby, C Turner, et al.
American Journal of Human Genetics
|
June 5, 2001
The Silver syndrome variant of hereditary spastic paraplegia maps to chromosome 11q12-q14, with evidence for genetic heterogeneity within this subtype
H Patel, P E Hart, T T Warner, et al.
Human Molecular Genetics
|
November 7, 2000
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity
S J Tabrizi, M Orth, J M Wilkinson, et al.
Neurology
|
May 11, 2005
High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study
S J Tabrizi, A M Blamire, D N Manners, et al.
Neurology
|
July 9, 2003
Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study
S J Tabrizi, A M Blamire, D N Manners, et al.
Neuropathology and Applied Neurobiology
|
July 29, 2020
Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinson's disease dementia
D Hansen, H Ling, T Lashley, et al.
Neurology
|
November 10, 2004
Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58)
S J Cano, T T Warner, J M Linacre, et al.
Page
of 5